Transfer Learning for Hematological Malignancy Diagnosis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current clinical practices face challenges in accurately diagnosing hematological malignancies due to laborious and error-prone manual gating of high-dimensional flow cytometry data, limited availability of labeled data, and the difficulty in collecting sufficient samples for each subtype, hindering the generalizability and applicability of machine learning and artificial intelligence algorithms.

Innovation Solution

A framework for transfer learning is introduced, utilizing a knowledge distillation step to condense insights from a source domain and a harmonized learning step to supplement information loss, enabling the model to correct predictions made by another model trained with sub-optimal data, thereby improving predictive capabilities across different hematological malignancies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If manual gating is used for diagnosing hematological malignancies, then diagnostic accuracy can be maintained with available tools, but the process becomes laborious and error-prone

Engineering Contradiction:
Improvediagnostic accuracyVSAvoidoperational simplicity
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The patent replaces manual gating (mechanical/physical operation) with machine learning and artificial intelligence algorithms (computational system). The system automatically analyzes high-dimensional flow cytometry data using trained models, substituting human manual analysis with automated computational processing, thereby maintaining diagnostic accuracy while eliminating labor and human error.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent implements self-service through automated machine learning models that independently analyze flow cytometry data without requiring manual intervention. The trained models automatically perform classification and diagnosis, making the system serve itself by processing data autonomously, thus improving operational simplicity while maintaining reliability.

Inventive Principle:
Principle #25Self-service

2Ease of manufacture

If machine learning algorithms are trained with limited labeled data for each leukemia subtype, then model training can proceed with available data, but generalizability and applicability are hindered

Engineering Contradiction:
Improvetraining feasibilityVSAvoidmodel generalizability
Core Design Contradiction:
Ease of manufactureVSAdaptability or versatility

Solution Approach 1:

The patent segments the learning process into two distinct phases: pre-training on source domain data (one or more leukemia subtypes) and fine-tuning on target domain data (specific leukemia subtype with limited labeled data). This segmentation allows the model to first learn general features from abundant source data, then adapt to specific target characteristics, thereby achieving both training feasibility and model generalizability.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent applies preliminary action by pre-training the machine learning model on source domain data before fine-tuning on the target domain. This preliminary training establishes a robust foundation of learned features that can be transferred to the target task, enabling the model to achieve good performance even with limited target labeled data, thus resolving the contradiction between training feasibility and generalizability.

Inventive Principle:
Principle #10Preliminary action

3Reliability

If knowledge is transferred across different hematological malignancy domains, then predictive capability improves, but privacy issues arise from transferring knowledge across databases

Engineering Contradiction:
Improvepredictive capabilityVSAvoidprivacy risks
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses fine-tuning as an intermediary process that bridges source domain pre-training and target domain application. Instead of directly transferring knowledge across databases (which creates privacy risks), the model serves as an intermediary that learns general patterns from source data and then adapts to target data through controlled fine-tuning, thereby maintaining predictive capability while mitigating privacy issues through a staged knowledge transfer approach.

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentUS20230228756A1Transfer learning across hematological malignancies
Publication Date: 2023.07.20 AHEAD INTELLIGENCE LTD
  • US20230228756A1 patent drawing
  • US20230228756A1 patent drawing
  • US20230228756A1 patent drawing

AI summary

Introduced here is an approach to improving the automatic identification of hematological malignancies by taking advantage of established databases through transfer learning. At a high level, this approach attempts to address the cross-domain gap by preserving knowledge of the source domain for better optimization of the target domain.